Glioblastoma is a dangerous brain malignancy known for its quick growth and insensitivity to typical treatments. Studies are constantly underway to identify new therapeutic strategies, and recently, a new biomarker named LCA168 has emerged as a potential target for GBM treatment. LCA168 is a protein that is highly expressed in glioblastoma cells c